Dustri Online Services

Search Results

Books: 0	Journals: 1	Articles: 1

Case  Report

Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes 

Srecko Marusic, Matea Staresinic, and Maja Cigrovski Berkovic

Price
42.00 $

Price

42.00 $

Add to Cart ###ENGLISH_ABSTRACT_LINK### ###FREE_ENGLISH_ARTICLE_DOWNLIAD_LINK###

Volume 64 (2026) p. 455 - 458

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 64 – No. 8/2026 (455-458)

Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes 

Srecko Marusic¹#²#³, Matea Staresinic⁴, and Maja Cigrovski Berkovic⁵

¹Department of Endocrinology and Clinical Pharmacology, University Hospital Dubrava, ²School of Medicine, ³Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, ⁴Faculty of Medicine, University of Rijeka, Rijeka, and ⁵Department for Sport and Exercise Medicine, Faculty of Kinesiology, University of Zagreb, Zagreb, Croatia
Objective: Although uncommon, medications may induce unpleasant body odor, potentially leading to psychosocial distress and reduced treatment adherence. To date, unpleasant body odor has not been recognized as an adverse effect of dulaglutide. We report a novel case of dulaglutide-associated body odor, confirmed by dechallenge and rechallenge.
Case report: A 57-year-old man with a 6-year history of type 2 diabetes mellitus and hypertension was initiated on dulaglutide due to inadequate glycemic control and obesity. Two weeks after treatment initiation, an unpleasant body odor was noted by family members and colleagues. No changes in diet, hygiene practices, or concomitant medications were reported. Dermatological examination and extensive laboratory evaluation excluded infectious, metabolic, and endocrine causes. The odor resolved ~ 10 days after discontinuation of dulaglutide. Upon rechallenge, the odor recurred, confirming a causal relationship. Dulaglutide was permanently discontinued, and treatment was switched to semaglutide, after which the body odor did not recur and glycemic control improved. According to the Naranjo Adverse Drug Reaction Probability Scale, the association was classified as probable.
Conclusion: This case highlights a rare and previously unreported adverse effect of dulaglutide. Although not medically serious, drug-induced body odor may substantially impair quality of life and treatment adherence.Correspondence to:
Srecko Marusic
Department of Endocrinology and Clinical Pharmacology
University Hospital Dubrava
Av. Gojka Suska 6, 10000 Zagreb, Croatia
Email: [email protected]

Warenkorb Übersicht

Warenkorb Übersicht
Typ	Anz	Rabatt	MwSt	Preis
Der Warenkorb ist leer

Ihr Warenkorb

Search Results

Warenkorb Übersicht

Senden Sie uns eine E-Mail